|Articles|August 1, 2002
Developing New Drugs in 1000 Days
Everybody wants faster cycles and and quicker turnarounds with NDAs. In the U.S., will it soon be possible to go from testing to approval in 1000 days?
Advertisement
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
2
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
3
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
4
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
